影响因子的重量级对手来了--CiteScore问世

2016-12-16 科学网 孙学军 科学网 孙学军

汤森路透影响因子是评价学术期刊的重要指标,近年因为被滥用也饱受争议。虽然也有不少取代方案,但影响因子在学术评价中的重要地位一直没有受到实质性挑战。2016年12月8日,学术出版巨头爱思唯尔终于拿出自己的期刊影响因子评分系统CiteScore,将成为经典期刊影响影响因子的最大挑战对手。这个爱思唯尔影响因子的计算公式和汤森路透影响因子类似,但是有一些自己的特色。大概差别有如下6个方面:1,汤森路透影响

汤森路透影响因子是评价学术期刊的重要指标,近年因为被滥用也饱受争议。虽然也有不少取代方案,但影响因子在学术评价中的重要地位一直没有受到实质性挑战。2016年12月8日,学术出版巨头爱思唯尔终于拿出自己的期刊影响因子评分系统CiteScore,将成为经典期刊影响影响因子的最大挑战对手。


这个爱思唯尔影响因子的计算公式和汤森路透影响因子类似,但是有一些自己的特色。大概差别有如下6个方面:

1,汤森路透影响因子只有11000本期刊,爱思唯尔影响因子覆盖的期刊数量增大1倍,包括22000种期刊。

2,计算公式也进行了调整,汤森路透影响因子是某期刊连续2年论文在第3年度的篇均引用次数,爱思唯尔影响因子则是期刊连续3年论文在第4年度的篇均引用次数。

3,汤森路透影响因子每年只公布一次影响因子,爱思唯尔则有一个最新年度预测影响因子。

4,汤森路透影响因子收费,爱思唯尔的影响因子系统是免费使用的。

5,汤森路透影响因子引用包括所有文章类型,但计算平均数时不包括通信、评论等小型文章,爱思唯尔的影响因子不区分文章类型。

6,汤森路透影响因子没有学科领域的区分,爱思唯尔的影响因子有不同学科领域的排名。

分析家认为,如果爱氏影响因子流行,将会进一步推动期刊为提高各种的影响因子的努力。但这需要面临不小的挑战。这个新的影响因子并没有在理念上有什么改进,最多不过是汤森路透影响因子的优化版。这样的改进并不能扭转影响因子给学术评价带来的负面影响,因为这已经导致许多学术机构和学者将杂志影响因子作为学术水平的代名词,这显然是南辕北辙,因为期刊影响因子不能代表论文的学术贡献,无法体现具体一篇学术论文的学术水平。

伦敦国王学院结构生物学家Stephen Curry说,使用期刊影响因子的时候,应该如“香烟有害健康”一样进行警示标注。利用影响因子进行学术评价是当今学术界许多罪恶的根源。

爱思唯尔认为发布自己的期刊影响因子是响应作者和杂志编辑的要求,爱思唯尔拥有自己的期刊引用数据库Scopus,发布自己的影响因子理所当然。

从使用效果上看,一些高端期刊的影响因子似乎都全面下降,例如《自然》、《科学》、《柳叶刀》都下降许多。爱思唯尔的影响因子包括所有文章类型,这不同于汤森路透影响因子引用包括所有论文,但是分母不计算通信、评论、新闻等小论文。因此,爱思唯尔的影响因子的计算方法影响因子平均降低是必然的。

《柳叶刀》和《自然》杂志拒绝评价这一新的影响因子面世。《科学》杂志主编Jeremy Berg说,《科学》杂志对自己设置的非学术报告和论文栏目非常骄傲,只利用引用次数的评价方式是对这种非学术论文价值的低估。爱思唯尔方面的负责人认为,新的期刊影响因子评价系统不只包括简单的分数,也包括在不同领域的相对排名,例如《柳叶刀》在普通医学领域的1,549本杂志中排25名,超过98%的同类期刊。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1738506, encodeId=0cad1e38506c1, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Fri Jan 27 18:09:00 CST 2017, time=2017-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561985, encodeId=f0311561985b1, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Dec 18 01:09:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163478, encodeId=29131634e8be, content=学习一下,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Dec 17 10:42:26 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163232, encodeId=f4ee16323270, content=换汤不换药的评价方式, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Fri Dec 16 11:30:06 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163222, encodeId=30f01632221e, content=不知道会不会影响中国的晋升评判标准。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 16 10:29:06 CST 2016, time=2016-12-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1738506, encodeId=0cad1e38506c1, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Fri Jan 27 18:09:00 CST 2017, time=2017-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561985, encodeId=f0311561985b1, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Dec 18 01:09:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163478, encodeId=29131634e8be, content=学习一下,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Dec 17 10:42:26 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163232, encodeId=f4ee16323270, content=换汤不换药的评价方式, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Fri Dec 16 11:30:06 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163222, encodeId=30f01632221e, content=不知道会不会影响中国的晋升评判标准。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 16 10:29:06 CST 2016, time=2016-12-16, status=1, ipAttribution=)]
    2016-12-18 docwu2019
  3. [GetPortalCommentsPageByObjectIdResponse(id=1738506, encodeId=0cad1e38506c1, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Fri Jan 27 18:09:00 CST 2017, time=2017-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561985, encodeId=f0311561985b1, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Dec 18 01:09:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163478, encodeId=29131634e8be, content=学习一下,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Dec 17 10:42:26 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163232, encodeId=f4ee16323270, content=换汤不换药的评价方式, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Fri Dec 16 11:30:06 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163222, encodeId=30f01632221e, content=不知道会不会影响中国的晋升评判标准。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 16 10:29:06 CST 2016, time=2016-12-16, status=1, ipAttribution=)]
    2016-12-17 虈亣靌

    学习一下,谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1738506, encodeId=0cad1e38506c1, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Fri Jan 27 18:09:00 CST 2017, time=2017-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561985, encodeId=f0311561985b1, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Dec 18 01:09:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163478, encodeId=29131634e8be, content=学习一下,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Dec 17 10:42:26 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163232, encodeId=f4ee16323270, content=换汤不换药的评价方式, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Fri Dec 16 11:30:06 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163222, encodeId=30f01632221e, content=不知道会不会影响中国的晋升评判标准。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 16 10:29:06 CST 2016, time=2016-12-16, status=1, ipAttribution=)]
    2016-12-16 Jin Chou

    换汤不换药的评价方式

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1738506, encodeId=0cad1e38506c1, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Fri Jan 27 18:09:00 CST 2017, time=2017-01-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561985, encodeId=f0311561985b1, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Sun Dec 18 01:09:00 CST 2016, time=2016-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163478, encodeId=29131634e8be, content=学习一下,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zMoyicyo6ia9f4IuLQAwZoxD6Hx4ibd5CMcOCYhStY6oDibbKK6O2X8iaicldO5ib8j1iapOIobIKCGiczU2A/0, createdBy=56251941490, createdName=虈亣靌, createdTime=Sat Dec 17 10:42:26 CST 2016, time=2016-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163232, encodeId=f4ee16323270, content=换汤不换药的评价方式, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/ajNVdqHZLLD1O97y3am76k8v12uX92l8MnMUZBZIrorphCDWyEYgqDulOfDXQZLWGiaSibbvm6F0ficxxxDMzwY9g/132, createdBy=bae077124, createdName=Jin Chou, createdTime=Fri Dec 16 11:30:06 CST 2016, time=2016-12-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=163222, encodeId=30f01632221e, content=不知道会不会影响中国的晋升评判标准。, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160616/IMG5762A3665DC7B3997.jpg, createdBy=df0a1649089, createdName=ys2323, createdTime=Fri Dec 16 10:29:06 CST 2016, time=2016-12-16, status=1, ipAttribution=)]
    2016-12-16 ys2323

    不知道会不会影响中国的晋升评判标准。

    0

相关资讯

美国微生物学会(ASM)回应"废弃影响因子"

美国微生物学会CEO Stefano Bertuzzi。图片来源:美国微生物学会美国微生物学会(ASM)7月11日在官网上宣布,旗下期刊不再支持影响因子(相关报道)。美国微生物学会表示,这一扭曲的评价系统损害了科学本身,阻碍了科研工作的交流。科学网论文频道(微博)就此事通过邮件联系了美国微生物学会CEO,Stefano Bertuzzi博士,并请他就读者关心的一些问题作了回应。科学网论文频道:除了

分析表明期刊影响因子价值被片面夸大

讨厌期刊影响因子?新研究给你另一个原因。图片来源:David Malakoff科学家对期刊影响因子(JIF)可谓又爱又恨。JIF是用于给技术类期刊权威性排名次的衡量标准。他们不只用其决定向哪里提交研究论文,还包括评价同行以及影响谁得到工作机会、终身职位以及项目资金。所有这些均要依赖这一简单、易读的数据。然而,很多人认为一份期刊的影响因子是无用的,或者甚至有损于科学界,应当不予理会。为了设法进一步了

Nature:影响因子改革,势在必行!

影响因子的局限性 关于影响因子的种种负面意见,恐怕主要集中在其对学者个人评价造成的影响。汤森·路透集团发言人Heidi Siegel表示,期刊影响因子 (JIF) 是描述期刊产出的一种粗略指标,不应当作为学者个人能力或者单个文章质量的评价标准。“我们相信对期刊整体影响力的衡量非常重要,而这正是期刊影响因子的作用。”当然,这可能是汤森·路透最后一次就此问题发言了。 尽管如此,很多学者、投

谷歌学术H5指数与影响因子本质区别:中位数还是平均数

每年汤森路透(Thomson Routers)的期刊引用报告(Journal Citation Report, JCR)在中国都引起了高度的关注。原因是在中国科研评价中,科研论文是否发表在被科学引文索引(Science Citation Index, SCI)或科学引文索引扩展版(Science Citation Index Expanded, SCI-E)收录的杂志上,以及该杂志的影响因子的